

Eli Avisar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7550051/publications.pdf>

Version: 2024-02-01

43
papers

935
citations

840776

11
h-index

454955

30
g-index

43
all docs

43
docs citations

43
times ranked

1350
citing authors

#	ARTICLE	IF	CITATIONS
1	Axillary Response to Neoadjuvant Therapy in Node-Positive, Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients: Predictors and Oncologic Outcomes. <i>Annals of Surgical Oncology</i> , 2022, 29, 4092-4101.	1.5	2
2	ASO Visual Abstract: Axillary Response to Neoadjuvant Therapy in Node-Positive ER+/HER2- Breast Cancer Patients—Predictors and Oncologic Outcomes. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
3	Persistent and interdependent: Racial disparities and their mechanisms in postmastectomy breast reconstruction. <i>Surgery</i> , 2022, 172, 25-30.	1.9	2
4	Evaluation of Simplified Lymphatic Microsurgical Preventing Healing Approach (SLYMPHA) for the prevention of breast cancer-related lymphedema after axillary lymph node dissection using bioimpedance spectroscopy. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1713-1717.	1.0	6
5	The Senologic International Society Survey on Ductal Carcinoma & In Situ: Present and Future. <i>The Journal of Breast Health</i> , 2022, 18, 205-221.	1.0	3
6	The Usefulness of the Pretreatment Neutrophil/Lymphocyte Ratio as a Predictor of the 5-Year Survival in Stage 1–3 Triple Negative Breast Cancer Patients. <i>Breast Care</i> , 2021, 16, 43-49.	1.4	0
7	Diagnostic application of cyclin D1 fluorescent in situ hybridization for histologically undetermined early lesions of acral melanoma in situ: A case series. <i>Annals of Diagnostic Pathology</i> , 2021, 50, 151681.	1.3	5
8	Overcoming disparities: Multidisciplinary breast cancer care at a public safety net hospital. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 197-206.	2.5	11
9	Breast Cancer Management During the COVID-19 Pandemic: The Senologic International Society Survey. <i>The Journal of Breast Health</i> , 2021, 17, 188-196.	1.0	9
10	Axillary response rates to neoadjuvant chemotherapy in breast cancer patients with advanced nodal disease. <i>Journal of Surgical Oncology</i> , 2021, 124, 25-32.	1.7	3
11	Long-term results of simplified lymphatic microsurgical preventing healing approach (SLYMPHA) for the prevention of breast cancer-related clinical lymphedema after axillary lymph node dissection.. <i>Journal of Clinical Oncology</i> , 2021, 39, 514-514.	1.6	0
12	Simplified lymphatic microsurgical preventing healing approach (SLYMPHA) for the prevention of breast cancer-related lymphedema after axillary lymph node dissection.. <i>Journal of Clinical Oncology</i> , 2021, 39, e12581-e12581.	1.6	0
13	Axillary Reverse Lymphatic Mapping in the Treatment for Axillary Accessory Breast Cancer: A Case Report and Review of Management. <i>The Journal of Breast Health</i> , 2021, 18, 0-0.	1.0	1
14	Surgical Management of the Axilla in Patients with Occult Breast Cancer (cT0 N+) After Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2020, 27, 1830-1841.	1.5	12
15	The Impact of Advanced Image-Guided Breast Surgery and Oncoplastic Techniques on Margin Positivity in Breast Conserving Surgery. <i>Cureus</i> , 2020, 12, e11831.	0.5	0
16	Evaluation of Simplified Lymphatic Microsurgical Preventing Healing Approach (S-LYMPHA) for the Prevention of Breast Cancer–Related Clinical Lymphedema After Axillary Lymph Node Dissection. <i>Annals of Surgery</i> , 2019, 270, 1156-1160.	4.2	35
17	Post Mastectomy Radiation for Stage II Breast Cancer Patients with T1/T2 Lesions. <i>The Journal of Breast Health</i> , 2019, 15, 71-75.	1.0	2
18	Response to Comment on “Annals of Surgery Response to Letter to the Editor”. <i>Annals of Surgery</i> , 2019, 270, e30-e31.	4.2	0

#	ARTICLE	IF	CITATIONS
19	Stratifying SLN incidence in intermediate thickness melanoma patients. American Journal of Surgery, 2018, 215, 699-706.	1.8	26
20	The role of matricellular proteins and tissue stiffness in breast cancer: a systematic review. Future Oncology, 2018, 14, 1601-1627.	2.4	12
21	Management of the positive axilla in 2017. Breast Cancer Research and Treatment, 2017, 163, 413-415.	2.5	3
22	Is pelvic sentinel node biopsy necessary for lower extremity and trunk melanomas?. American Journal of Surgery, 2017, 213, 921-925.	1.8	4
23	Management of the Positive Axilla in 2017. Cureus, 2017, 9, e1216.	0.5	2
24	Evaluation of simplified lymphatic microsurgical preventing healing approach (SLYMPHA) for the prevention of breast cancer-related clinical lymphedema after axillary lymph node dissection.. Journal of Clinical Oncology, 2017, 35, 563-563.	1.6	0
25	A rare complication resulting in a rare disease: radiation-induced male breast cancer. BMJ Case Reports, 2016, 2016, bcr2015211874.	0.5	1
26	Internal Mammary Node Irradiation: Does One Treatment Fit All?. Journal of Clinical Oncology, 2016, 34, 2671-2671.	1.6	1
27	A tailored approach to regional nodal irradiation. Breast Cancer Research and Treatment, 2016, 155, 1-2.	2.5	5
28	Neoadjuvant and adjuvant, floxuridine, leucovorin, oxaliplatin, and docetaxel (FLOD) in patients with locally advanced operable gastroesophageal adenocarcinoma: A phase II study with pathologic responses and long term follow-up.. Journal of Clinical Oncology, 2016, 34, 124-124.	1.6	0
29	Brief cognitive-behavioral and relaxation training interventions for breast cancer: A randomized controlled trial.. Journal of Consulting and Clinical Psychology, 2015, 83, 677-688.	2.0	78
30	Predictors of Surgery Types after Neoadjuvant Therapy for Advanced Stage Breast Cancer: Analysis from Florida Population-Based Cancer Registry (1996-2009). Breast Cancer: Basic and Clinical Research, 2015, 9, BCBCR.S31503.	1.1	1
31	Disparities in Overall Survival for Male Breast Cancer Patients in the State of Florida (1996-2007). Clinical Breast Cancer, 2015, 15, e177-e187.	2.4	13
32	Prognosis of metastatic internal mammary sentinel nodes (IMSN) in breast cancer.. Journal of Clinical Oncology, 2014, 32, 103-103.	1.6	2
33	Factors associated with increasing rates of contralateral prophylactic mastectomy.. Journal of Clinical Oncology, 2014, 32, 57-57.	1.6	0
34	Clinicopathologic Predictors of Sentinel Lymph Node Metastasis in Thin Melanoma. Journal of Clinical Oncology, 2013, 31, 4387-4393.	1.6	204
35	Factors Predictive of the Status of Sentinel Lymph Nodes in Melanoma Patients from a Large Multicenter Database. Annals of Surgical Oncology, 2011, 18, 3593-3600.	1.5	78
36	Predictive value of BI-RADS classification for breast imaging in women under age 50. Breast Cancer Research and Treatment, 2011, 130, 819-823.	2.5	5

#	ARTICLE	IF	CITATIONS
37	A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Research and Treatment, 2008, 111, 541-547.	2.5	222
38	Use of PET probe in surgical oncology. Journal of Surgical Oncology, 2008, 97, 369-371.	1.7	1
39	Internal mammary sentinel node biopsy for breast cancer. American Journal of Surgery, 2008, 196, 490-494.	1.8	16
40	Interleukin-21 Induces Cell Cycle Arrest and Apoptosis of Diffuse Large B-Cell Lymphomas (DLBCL) Via Activation of STAT3 and Upregulation of C-Myc. Blood, 2008, 112, 601-601.	1.4	2
41	Prognostic Factors in Node-Negative Male Breast Cancer. Clinical Breast Cancer, 2006, 7, 331-335.	2.4	23
42	Impact of Sentinel Node Status and Other Risk Factors on the Clinical Outcome of Head and Neck Melanoma Patients. JAMA Otolaryngology, 2006, 132, 370.	1.2	93
43	Pure mucinous carcinoma of the breast: A clinicopathologic correlation study. Annals of Surgical Oncology, 1998, 5, 447-451.	1.5	52